News Related to Japan

Related coverage linked through entity extraction aliases.

FDA Approves AstraZeneca and Daiichi Sankyo's Datroway for First-Line Triple-Negative Breast Cancer

May 22, 2026

FDA approves AstraZeneca and Daiichi Sankyo's Datroway for first-line TNBC patients not eligible for PD-1/L1 inhibitors, based on Phase III TROPION-Breast02 data showing a 21% reduction in risk of death versus chemotherapy.

Novartis reports new Pluvicto data in metastatic hormone-sensitive prostate cancer

May 18, 2026

Novartis reported Phase III PSMAddition data showing Pluvicto plus standard of care cut the risk of PSA progression by 58% in PSMA-positive metastatic hormone-sensitive prostate cancer. Regulatory decisions in the United States, China and Japan are expected in the second half of 2026.